Dr Reddy Laboratories : Copy of Newspaper Publication

January 29, 2022

To,

The Secretary/Executive Director

BSE Limited

National Stock Exchange of India Limited

New York Stock Exchange, Inc.

NSE-IFSC Limited

Dear Sir/Madam,

Sub: Newspaper advertisement regarding financial results for the quarter and nine months ended December 31, 2021

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, please find enclosed copies of newspaper advertisement regarding the financial results of the company for the quarter and nine months ended December 31, 2021 as published in Business Standard and Andhra Prabha on January 29, 2022.

This is for your information and records.

With regards,

Vivek Mittal

Global General Counsel and Compliance Officer

Encl: as above

2	HYDERABAD | 29 JANUARY 2022	1
>		•

Extract of unaudited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter and nine months ended 31 December 2021 prepared in compliance with Indian Accounting Standards

All amounts in Indian Rupees millions

			Consolidated
Sl.		Quarter	Nine Months	Quarter
Particulars	ended	ended	ended
No.
		31.12.2021	31.12.2021	31.12.2020
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total Revenue from operations	53,383	160,703	49,419
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	9,742	28,025	2,949
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	9,742	28,025	2,949
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	7,093	20,855	279
5	Total Comprehensive Income for the period	5,855	18,457	4,011
6	Equity Share Capital	832	832	831

• Earnings per share (in Rupees) per Rs. 5/- share

	Basic	42.75	125.74	1.68
	Diluted	42.65	125.43	1.67
			Standalone
Sl.		Quarter	Nine Months	Quarter
Particulars	ended	ended	ended
No.
		31.12.2021	31.12.2021	31.12.2020
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total Revenue from operations	34,796	107,365	34,082
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	4,639	16,571	6,179
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	4,639	16,571	6,179
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	3,411	12,035	4,437
5	Total Comprehensive Income for the period	3,543	11,958	4,546
6	Equity Share Capital	832	832	831

• Earnings per share (in Rupees) per Rs. 5/- share

Basic	20.55	72.56	26.74
Diluted	20.51	72.38	26.66

Notes:

• The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website: www.bseindia.com and www.nseindia.com and also on the Company's website: www.drreddys.com.

• The unaudited results have been reviewed by the Audit Committee of the Board at their meeting held on 27 January 2022 and approved by the Board of Directors of the Company at their meeting held on 28 January 2022.

		By order of the Board
		For Dr. Reddy's Laboratories Limited
Place	: Hyderabad
Date	: 28 January 2022	G V Prasad
		Co-Chairman & Managing Director

Dr. REDDY'S LABORATORIES LIMITED

Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India

CIN: L85195TG1984PLC004507, Tel: [phone], Fax: [phone]

email: [e-mail], website: www.drreddys.com

VIVEK MITTA L

Digitally signed by VIVEK MITTAL

Date:

2022.01.30 15:05:06 +05'30'

Andhra Prabha - January 29, 2022

VIVEKDigitally signed by

VIVEK MITTAL

MITT Date:2022.01.30 AL 15:05:21

+05'30'